Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Rare Diseases

Squamous Intraepithelial Lesions of the Cervix

Carcinoma

Carcinoma, Squamous Cell

Carcinoma in Situ

Uterine Cervical Dysplasia

Precancerous Conditions

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Cervical Intraepithelial Neoplasia

Anti-Infective Agents

All Drugs and Chemicals

Antineoplastic Agents

Vitamins

Acetic Acid

Retinol acetate

Detection of anal HSIL in a routine colonoscopy by using acetic acid and NBI/BLI.

Detection of anal HSIL in a routine colonoscopy.

Andreia Albuquerque, MD PhD

HIV-positive patients, women with a history of genital neoplasia and patients under pharmacologically immunosuppression (e.g. transplanted recipients, Crohn´s disease and Lupus) are a high-risk population for anal human-papillomavirus infection and associated complications, like anal precancerous lesions and anal squamous cell carcinoma. There is a lack of information on the prevalence of anal precancerous detected by routine colonoscopy in this population, by evaluating the squamocolumnar junction (the most susceptible area for lesions) during this procedure. Given, the increasing incidence rates of anal squamous cell carcinoma expected for the next two decades and the increase number of at-risk patients, the possible benefit of routine endoscopy in the diagnosis of anal precancerous lesions needs to be further explored.

Procedures in all patients:

1. Digital anorectal evaluation
2. Colonoscopy with retroflection and visualization of the anal squamocolumnar junction
3. After identification of this area 5% acetic acid will be applied.
4. Visualization under NBI/BLI.
5. Biopsies of all the suspected lesions of anal high-grade squamous lesions (HSIL).

ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS.

PREVALENCE OF ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS DETECTED BY ROUTINE COLONOSCOPY (PACCO STUDY)

University Fernando Pessoa

Digestive System Diseases

Infections

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Anus Neoplasms

Warts

Condylomata Acuminata

Penile Neoplasms

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Anus Diseases

Rectal Diseases

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases, Male

Penile Diseases

Male Urogenital Diseases

Penile Cancer

Anal Cancer

Vaccines

Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5mL/each dose).

Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).

Placebo among 18-45 yrs

Placebo among 9-17 yrs

Ting Huang

To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study

Subjects with solicited and unsolicited AEs

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

Immunogenicity were assessed by the GMT of anti HPV6/11/16/18/33/45/52/58 neutralizing antibodies after day 31 post last dose, among the subjects who were aged 9-45

Immunogenicity were assessed by the seroconversion rate of anti HPV6/11/16/18/33/45/52/58 neutralizing antibodies after day 31 post last dose, among the subjects who were aged 9-45 and seronegative before vaccination

Immunogenicity were assessed by the seroconversion rate and GMT of anti HPV6/11/16/18/33/45/52/58 IgG antibodies after day 31 post last dose, among the subjects who were aged 9-45 and seronegative before vaccination

Immunogenicity were assessed by the seroconversion rate and GMT (4-fold increase rate) of anti HPV6/11/16/18/33/45/52/58 IgG and neutralizing antibodies after day 31 post last dose, among the subjects who were aged 9-45 and seropositive before vaccination

Shanghai Bovax Biotechnology Co., Ltd.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS.	NCT05060640	AIN3 AIN2 HSIL, High Grad...	Detection of an...	-	University Fernando Pessoa
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old	NCT05518201	Penile Cancer Anal Cancer PIN-1 PIN-2 PIN-3 AIN1 AIN2 AIN3 Genital Wart	Placebo among 1... Placebo among 9...	9 Years - 45 Years	Shanghai Bovax Biotechnology Co., Ltd.
ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS.	NCT05060640	AIN3 AIN2 HSIL, High Grad...	Detection of an...	-	University Fernando Pessoa
ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS.	NCT05060640	AIN3 AIN2 HSIL, High Grad...	Detection of an...	-	University Fernando Pessoa
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old	NCT05518201	Penile Cancer Anal Cancer PIN-1 PIN-2 PIN-3 AIN1 AIN2 AIN3 Genital Wart	Placebo among 1... Placebo among 9...	9 Years - 45 Years	Shanghai Bovax Biotechnology Co., Ltd.

Spots Global Cancer Trial Database for ain3

Every month we try and update this database with for ain3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ain3

Every month we try and update this database with for ain3 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ain3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.